ABT-263
Bcl-2 family inhibitor, Senolytic agent / Potent and selective Bcl-2 family inhibitor / BH3 domain mimetic which binds to Bcl-2, Bcl-xL and Bcl-w (Ki<1 nM). A useful tool compound which has shown interesting results in various cancer clinical trials2. Synergizes with deoxyglucose and other agents, inducing apoptosis in cancer cells in a xenograft mouse model3. A novel senolytic agent, inducing apoptosis preferentially in senescent cells in a cell type-restricted manner4.
Biochemicals & reagents
923564-51-6
Navitoclax
1) Tse et al. (2008), ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor; Cancer Res., 68 3421 2) Vogler et al. (2009), Bcl-2 inhibitors: small molecules with a big impact on cancer therapy; Cell Death Differ., 16 360 3) Yamaguchi et al. (2011), Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy; PLoS ONE, 6(9) e24102 4) Zhu et al. (2016), Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors; Aging Cell, 15 428
-20°C
TARGET: Bcl-2 -- PATHWAY: Apoptosis inducer; Mitochondrial function; Senescence; Bcl; Senescence -- RESEARCH AREA: Cell death; Neuroscience; Stem cells -- DISEASE AREA: Cancer; AgeingNeurodegeneration